Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1993-6-11
pubmed:abstractText
The pharmacokinetics of rufloxacin were investigated in normal subjects and in patients with various degrees of renal failure after the administration of a single oral 400-mg dose. Twenty-four subjects were classified by glomerular filtration rate (GFR) normalized for body surface area. Group 1 subjects had GFRs of > 80 ml/min, group 2 subjects had GFRs from 30 to 80 ml/min, group 3 subjects had GFRs from 8 to 29 ml/min, and group 4 subjects had GFRs of < 8 ml/min. The patients in group 4 were on continuous peritoneal dialysis or underwent hemodialysis 48 h after dosing. Plasma and urinary rufloxacin concentrations were determined by high-performance liquid chromatography. A two-compartment model was used to calculate rufloxacin pharmacokinetic parameters. Apparent total body clearance of the drug was linearly related to GFR (r = 0.696; P < 0.01). The elimination half-life increased proportionally with the severity of renal impairment, with values of 30 +/- 3, 36 +/- 5, and 44 +/- 3 h in groups 1, 2, and 3, respectively. In patients with moderate renal failure, dosage adjustment of rufloxacin is not needed. The rufloxacin dose interval should be prolonged to 48 h as the GFR falls below 30 ml/min/1.73 m2.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-1244564, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-1312263, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-1316313, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-1324239, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-1329618, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-1662127, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-1662190, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-1665122, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-1667783, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-1917050, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-2024974, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-2976092, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-3253051, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-3282749, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-3820216, http://linkedlifedata.com/resource/pubmed/commentcorrection/8388194-4980763
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
637-41
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Pharmacokinetics of rufloxacin in patients with impaired renal function.
pubmed:affiliation
Renal Unit, Guy's Hospital, London, United Kingdom.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't